PhRMA chief dings health insurers over drug prices at their own conference
PhRMA’s Steve Ubl used an in-person health insurance industry conference to blame insurers for making people pay too much for drugs.
Related Articles
Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition
Ultragenyx has found early success with its experimental treatment for the rare disease Angelman syndrome.
Hospital price transparency rules are seeding a new crop of health tech startups
Hospital and health insurance pricing data surfaced by new federal transparency rules are creating an opportunity for startups to help patients fight exorbitant medical bills.
Covid ignited a global controversy over what is an airborne disease. The WHO just expanded its definition
A WHO advisory committee outlined a new set of definitions that more accurately reflect the science of airborne disease transmission.
Second-generation mosquito nets prevented 13 million malaria cases in large pilot programs
Second-generation mosquito nets prevented 13 million malaria cases and 25,000 deaths in large pilot programs.
H5N1 bird flu in U.S. cattle: A wake-up call to action
Comparisons to seasonal flu management underestimate the unique challenges posed by H5N1 bird flu.
Health disparities and premature deaths run deep, even in best-performing states
A new analysis of health inequities shows that every state has deep racial and ethnic disparities in the performance of their health care systems.
Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Kids can’t wait any longer for social media safety
Millions of children are coming of age in an unrestricted and unprotected digital universe. They need guardrails that can keep them safe.
USDA faulted for disclosing scant information about outbreaks of H5N1 avian flu in cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.